Best practices for first-in-human biopharma trials in Guatemala

Phase I drug trials in Guatemala follow Agreement 206-2021. Ethics approval comes before DRCPFA. Early research is not an efficacy promise.

Regulatory sources checked November 7, 2026. General sponsor guidance, not legal advice or an approval guarantee.

A first-in-human biopharma study in Guatemala is a drug Phase I problem under Ministerial Agreement 206-2021. The competent authority is MSPAS through DRCPFA. It is not a Colombian or Mexican file, and it is not the dossier used for an investigational medical device.

Phase I, in the norm’s own terms, is the first step in studying a substance in humans, including safety and pharmacokinetics. That is not a promise of efficacy and not a promise of direct benefit to the participant. Animal toxicity data are a filing requirement. They do not prove how the product will behave in people.

What section 45.1 asks for in Phase I

Section 45.1 addresses the ethics opinion, consent and assent where applicable, a detailed protocol, prior animal toxicity information, the investigator brochure, and a facility and staff suitable for Phase I. Each candidate needs its own assessment. This is not a statement that every drug or indication qualifies.

Section 101 lists alternative conditions for an investigational product, including preclinical research aligned with MSPAS research policies and priorities. Do not paraphrase that list as a blanket requirement for prior foreign approval, and do not read it as “every product is eligible.”

Ethics approval comes before DRCPFA

Sections 37.8 and 42 require a favorable ethics opinion before the application is presented to the Department. Use an ethics committee that is authorized for the work, with the expertise, submission rules, and meeting calendar that committee actually uses. The official portal lists more than one committee. Section 38.7 requires each committee to set its own operating procedures, meeting frequency, and maximum response time. A January 2026 roster is a snapshot, not proof that every listed committee is still authorized.

The protocol must be in Spanish (section 42.11). The investigator brochure may be in its original language with a Spanish summary (section 42.12). Confirm the language rule for every other document, including safety reports, instead of assuming the whole file is bilingual. A Spanish consent form makes understanding possible. Translation alone does not prove that a participant understood the study.

The authority clock is not startup

Section 47 states up to 30 business days after DRCPFA receives a complete file. If the authority asks for more information, the applicant has 15 business days to respond, with a written explanation if that response will be late, and the text then allows 15 business days for a final decision after the required information arrives. Ethics review, dossier preparation, queries, contracts, import, and activation sit outside that clock.

Before supply, section 103.1 requires the ethics and DRCPFA documentation the regulation calls for. Clinical-trial insurance must be in place before the study begins (section 11). Section 48 provides a one-year authorization and a renewal path. Use the current F-EC-a-01 and the registration forms on the MSPAS forms portal, and confirm the version when you file. The portal has listed version 04-2025 of F-EC-a-01, effective 3 November 2025.

Foreign data can be eligible for an FDA conversation under 21 CFR 812.28 only when that rule’s conditions are met. Eligibility is not clearance or approval. For a device, use the device dossier in section 43 rather than this Phase I list. ISO 14155 can inform device good-clinical-practice planning. This page does not claim that Agreement 206-2021 expressly adopts it.

The study-specific MSPAS pathway, including Phase I and device-investigation requirements, is on clinical trials in Guatemala.

Commercial device registration is a different file: Guatemala MSPAS registration and how to register a medical device in Guatemala. Acuerdo Gubernativo 712-99 and Norma Técnica 37 are a commercial framework, not a study permit.

Primary sources

Contact bioaccess® to request a Guatemala feasibility assessment. Bring the product description, development stage, preclinical evidence, proposed population, procedures, and follow-up.

Frequently asked questions

Who authorizes a Phase I drug trial in Guatemala?

MSPAS through DRCPFA, after an authorized ethics committee has approved the study. Do not address the Guatemala file to a foreign device or drug agency.

Does preclinical work prove the drug will help patients?

No. Preclinical toxicity information is part of the Phase I file. It does not establish human efficacy or promise a benefit to the participant.

Is a six-to-eight-week startup a Guatemala rule?

No. The published authority period is up to 30 business days from a complete file, with separate query time. It is not a total startup timeline.

← Back to Blog · Contact bioaccess®